Vepoloxamer Data Selected For Presentation At 57th Annual American Society Of Hematology (ASH) Meeting

16 Nov, 2015, 08:00 ET from Mast Therapeutics, Inc.

SAN DIEGO, Nov. 16, 2015 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, today announced that data from nonclinical studies investigating vepoloxamer, its lead product candidate, will be featured in three poster sessions at the 57th Annual American Society of Hematology (ASH) Meeting and Exposition. The ASH Meeting is being held at the Orange County Convention Center in Orlando, Florida, December 5 through December 8, 2015.

The studies to be presented demonstrate the anti-adhesive effects of vepoloxamer on sickle red blood cells (RBC) as well as its protective effects on the membranes of red blood cells and platelets.  In one study, vepoloxamer was shown to result in statistically significant reductions in the number of adherent sickle RBC to immobilized vascular cell adhesion molecule (VCAM) and reductions in hemolysis in blood from patients with sickle cell disease (SCD) (n=12).  In other studies, vepoloxamer was shown to preserve platelet function under extended storage conditions as well as prevent exposure of a marker of platelet damage (phosphatidyl serine) in blood samples from patients with SCD.

Dr. R. Martin Emanuele, Senior Vice President, Development, said: "These results are encouraging since they continue to demonstrate vepoloxamer's membrane protecting effects. Protecting the integrity of RBC and platelet membranes may be an important treatment goal in several clinical conditions but especially in sickle cell disease where hemolysis and platelet thrombosis are well known to be associated with worsening outcomes."

Poster Information:

  • A poster entitled "Evaluation of Purified Poloxamer -188 (vepoloxamer) on Sickle Red Blood Cell (RBC) Membrane Function Properties," will be presented by Dr. Jennell White on December 6, 2015 as part of the Hemoglobinopathies, Excluding Thalassemia – Clinical Program, Oral and Poster Abstracts Session: 114 in Hall A, Level 2.
  • A poster entitled "Functional Protection of Platelets By Tri-Block Polymer (Poloxamer-188) As Studied in Agonist Induced Platelet Aggregation Systems," will be presented by Dr. Nil Guler on December 5, 2015 as part of the Platelet Activation and Biochemistry Program: Oral and Poster Abstracts Session: 301 in Hall A, Level 2.
  • A poster entitled "Characterizing Cellular Interactions Contributing to Vaso-Occlusion in Patients with Sickle Cell Disease Utilizing a Novel Endothelialized Microfluidic Device," will be presented by Dr. Margo Rollins on December 7, 2015 as part of the Hemoglobinopathies, Excluding Thalassemia – Basic and Translational Science Program: Oral and Poster Abstracts Session: 113 in Hall A, Level 2.
  • Copies of the posters will be available concurrent with the presentations on the Company's website at: http://www.masttherapeutics.com/technology/publications/

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging its MAST platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer (also known as MST-188), its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes.  The Company is also developing AIR001, a sodium nitrite solution for inhalation via nebulizer, for the treatment of heart failure with preserved ejection fraction (HFpEF).

Vepoloxamer is an investigational new drug being tested in a pivotal Phase 3 study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in a Phase 2 study for the treatment of patients with chronic heart failure. AIR001 is an investigational new drug being tested in two institution-sponsored Phase 2a studies in patients with HFpEF. More information can be found on the Company's web site at www.masttherapeutics.com. (Twitter: @MastThera

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements may include, but are not limited to, statements relating to prospects for successful development and commercialization of the Company's investigational drugs, including vepoloxamer and AIR001, and anticipated timing of achievement of development milestones, such as commencement and completion of clinical studies or regulatory activities, and of announcement of study data. Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the uncertainty of outcomes in ongoing and future studies of the Company's product candidates and the risk that its product candidates, including vepoloxamer, may not demonstrate adequate safety, efficacy or tolerability in one or more such studies, including EPIC and the Phase 2 study of vepoloxamer in chronic heart failure; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a "clinical hold," and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the risk that, even if planned clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the potential that, even if clinical studies of a product candidate in one indication are successful, clinical studies in another indication may not be successful; the potential for additional nonclinical or clinical studies to be required prior to initiation of a planned clinical study; the Company's reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct of important aspects of development of its product candidates, including clinical studies, manufacturing, and regulatory activities for its product candidates, and that such third parties may fail to perform as expected; the risk that the Company may be required to repay its outstanding debt obligations at a time that could be detrimental to its financial condition, operations and/or business strategy; the Company's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for the Company to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner its product candidates at inopportune times or pursue less expensive but higher-risk and/or lower return development paths if it is unable to raise sufficient additional capital as needed; the risk that, even if the Company successfully develops a product candidate in one or more indications, it may not realize commercial success and may never achieve profitability; the risk that the Company is not able to adequately protect its intellectual property rights, through patents or otherwise, and prevent competitors from duplicating or developing equivalent versions of its product candidates or that the use or manufacture of its products or product candidates infringe the proprietary rights of others; and other risks and uncertainties more fully described in the Company's press releases and periodic filings with the Securities and Exchange Commission. The Company's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release  to reflect events or circumstances arising after the date hereof, except as may be required by law. 

Logo - http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a

 

SOURCE Mast Therapeutics, Inc.



RELATED LINKS

http://www.masttherapeutics.com